BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups
Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact
WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics.”
BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.
“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts
Media:
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com